Christopher G Proud Selected Research

Phenylephrine (Neo-Synephrine)

10/2016	Quantitative Non-canonical Amino Acid Tagging (QuaNCAT) Proteomics Identifies Distinct Patterns of Protein Synthesis Rapidly Induced by Hypertrophic Agents in Cardiomyocytes, Revealing New Aspects of Metabolic Remodeling.
6/2005	Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2).
7/2004	Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte.
11/2002	Regulation of the phosphorylation of elongation factor 2 by MEK-dependent signalling in adult rat cardiomyocytes.
11/2002	Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher G Proud Research Topics

Disease

37	Neoplasms (Cancer) 01/2022 - 01/2004
14	Starvation 01/2019 - 11/2002
9	Leukoencephalopathies 12/2015 - 11/2003
8	Cardiomegaly (Heart Hypertrophy) 10/2016 - 11/2002
6	Insulin Resistance 05/2024 - 01/2018
5	Tuberous Sclerosis (Bourneville's Disease) 04/2021 - 05/2005
5	Neoplasm Metastasis (Metastasis) 01/2019 - 04/2015
4	Obesity 05/2021 - 12/2020
4	Carcinogenesis 01/2021 - 08/2013
3	Hyperglycemia 06/2023 - 08/2008
3	Inflammation (Inflammations) 01/2022 - 01/2016
3	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2020
3	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2016 - 01/2004
3	Nervous System Diseases (Neurological Disorders) 12/2015 - 03/2012
3	Hypoxia (Hypoxemia) 05/2015 - 04/2009
2	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 10/2017
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2022 - 04/2011
2	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 01/2019
2	Dementia (Dementias) 01/2021 - 10/2017
2	Hepatocellular Carcinoma (Hepatoma) 01/2020 - 06/2007
2	Breast Neoplasms (Breast Cancer) 07/2017 - 06/2012
2	Acidosis 05/2015 - 04/2015
2	Hypertrophy 06/2013 - 07/2004
2	Ischemia 01/2007 - 10/2002
2	Brain Ischemia (Cerebral Ischemia) 01/2007 - 10/2002
2	Brain Diseases (Brain Disorder) 04/2006 - 11/2003
1	Liver Diseases (Liver Disease) 05/2024
1	Amyloid Plaque 01/2023
1	Extrahepatic Cholestasis 01/2022
1	Atherosclerosis 01/2022
1	Cholestasis 01/2022
1	Intrahepatic Cholestasis 01/2022
1	Liver Failure 01/2022
1	Gallbladder Diseases (Gall Bladder Disease) 01/2022
1	Atherosclerotic Plaque (Atheroma) 01/2022
1	Leukemia 07/2021
1	Overnutrition 02/2021
1	Thinness 02/2021
1	Weight Gain 02/2021
1	Neuroinflammatory Diseases 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 10/2020
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020
1	Liver Neoplasms (Liver Cancer) 01/2020

Drug/Important Bio-Agent (IBA)

42	Proteins (Proteins, Gene)FDA Link 01/2023 - 10/2002
20	Mechanistic Target of Rapamycin Complex 1IBA 05/2021 - 06/2007
12	Eukaryotic Initiation Factor-2B (Eukaryotic Initiation Factor 2B)IBA 01/2022 - 10/2002
10	Amino Acids FDA Link 01/2023 - 05/2005
10	Eukaryotic Initiation Factor-4EIBA 07/2021 - 12/2002
9	Phosphotransferases (Kinase)IBA 01/2022 - 10/2002
8	Insulin (Novolin)FDA Link 05/2024 - 05/2005
8	TOR Serine-Threonine KinasesIBA 05/2014 - 04/2005
7	Elongation Factor 2 KinaseIBA 01/2021 - 05/2015
6	Messenger RNA (mRNA)IBA 01/2022 - 01/2004
5	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 10/2016 - 11/2002
5	Peptide Initiation Factors (Initiation Factor)IBA 08/2015 - 10/2002
5	Sirolimus (Rapamycin)FDA Link 08/2015 - 06/2007
3	Protein Kinases (Protein Kinase)IBA 07/2021 - 11/2020
3	Glucose (Dextrose)FDA LinkGeneric 05/2021 - 01/2018
3	MTOR InhibitorsIBA 01/2021 - 08/2013
3	EnzymesIBA 07/2018 - 04/2009
2	Amyloid (Amyloid Fibrils)IBA 01/2023 - 10/2017
2	Glutamine (L-Glutamine)FDA Link 01/2022 - 01/2019
2	CholesterolIBA 01/2022 - 01/2017
2	LipidsIBA 02/2021 - 12/2020
2	Mitogen-Activated Protein KinasesIBA 12/2020 - 01/2019
2	Small Interfering RNA (siRNA)IBA 01/2020 - 01/2019
2	RNA (Ribonucleic Acid)IBA 10/2016 - 06/2012
2	Leucine (L-Leucine)FDA Link 01/2016 - 09/2014
2	70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA 08/2003 - 10/2002
2	Endothelin-1 (Endothelin 1)IBA 11/2002 - 11/2002
1	CytokinesIBA 06/2023
1	AdipokinesIBA 06/2023
1	Dietary ProteinsIBA 01/2023
1	tau Proteins (tau Protein)IBA 01/2023
1	Glutathione (Reduced Glutathione)IBA 01/2022
1	Bile Acids and Salts (Bile Acids)IBA 01/2022
1	Glutathione Disulfide (GSSG)FDA LinkGeneric 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	Ribosomal RNAIBA 01/2022
1	GW 6471IBA 01/2022
1	daisaikotoIBA 01/2022
1	Fenofibrate (CiL)FDA LinkGeneric 01/2022
1	tomivosertibIBA 07/2021
1	Peptide Elongation Factors (Elongation Factor)IBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 12/2020
1	Immune Checkpoint ProteinsIBA 11/2020
1	Immune Checkpoint InhibitorsIBA 11/2020
1	B7-H1 AntigenIBA 11/2020
1	Tacrolimus (Prograf)FDA LinkGeneric 10/2020
1	Immunosuppressive Agents (Immunosuppressants)IBA 10/2020
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 10/2020
1	Gefitinib (Iressa)FDA Link 01/2020
1	Eukaryotic Initiation Factor-2 (EIF 2)IBA 01/2020
1	Growth Factor ReceptorsIBA 01/2020
1	Peptide Elongation Factor 2 (EF-2)IBA 01/2020

Therapy/Procedure

11	Therapeutics 04/2021 - 08/2013
2	Caloric Restriction 05/2021 - 05/2013
2	Immunotherapy 01/2021 - 11/2020
1	Ligation 01/2022
1	Organ Transplantation 10/2020